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ABSTRACT
Purpose Low inspiratory force in patients with lung disease is
associated with poor deagglomeration and high throat deposition
when using dry powder inhalers (DPIs). The potential of two
reverse flow cyclone prototypes as spacers for commercial
carrier-based DPIs was investigated.
Methods Cyclohaler®, Accuhaler® and Easyhaler® were
tested with and without the spacers between 30 and
60 Lmin−1. Deposition of particles in the next generation
impactor and within the devices was determined by high
performance liquid chromatography.
Results Reduced induction port deposition of the emitted
particles from the cyclones was observed due to the high
retention of the drug within the spacers (e.g. salbutamol sulphate
(SS): 67.89±6.51% at 30 Lmin−1 in Cheng 1). Fine particle
fractions of aerosol as emitted from the cyclones were
substantially higher than the DPIs alone. Moreover, the
aerodynamic diameters of particles emitted from the cyclones
were halved compared to the DPIs alone (e.g. SS from the
Cyclohaler® at 4 kPa: 1.08±0.05 μm vs . 3.00±0.12 μm, with
and without Cheng 2, respectively) and unaltered with increased
flow rates.
Conclusion This work has shown the potential of employing a
cyclone spacer for commercial carrier-based DPIs to improve
inhaled drug delivery.
KEY WORDS cyclone . dry powder inhalers . fine particle
fraction . oropharyngeal deposition . spacers
INTRODUCTION
Passive dry powder inhalers (DPIs) have developed a strong
place in the therapy of pulmonary diseases over the last
25 years, even representing the dominant inhaled therapy in
some markets (1). One of the main advantages of DPIs
compared to metered dose inhalers (MDIs) is surely the
avoidance of a requirement for actuation-inhalation co-
ordination by the user (2). Nevertheless, passive DPIs pose
some major challenges as a universal therapy of lung diseases.
The de-aggregation of the formulation into an aerosol suitable
for inhalation is dependent on the interaction between a
powder formulation and the airflow which is drawn through
the device (3–5). Many patients with obstructive lung disease
are unable to generate an aerosol cloud through high
resistance devices (6). In traditional products, even with
formulations optimized for in vitro drug delivery, the in vivo
efficiency (lung deposition) of DPIs has been reported to be
low and to be variable (7). The degree of throat deposition has
been identified as a major cause of variability in efficiency of
marketed DPIs and MDIs (8).
The success of inhalation therapy depends on the complex
interaction between a powder formulation and the airflow
drawn through a DPI. In most cases the device design is
optimized tomaximize aerosolization of a specific formulation
using in vitro testing. The majority of DPIs (9) contain a blend
of micronized drug particles blended with non-respirable
carrier particles. Micronized particles which are not removed
from the carrier upon inhalation are unable to reach the lung,
depositing instead within the oropharynx (5). Oropharyngeal
deposition is well understood withMDIs, where large droplets
with high velocity deposit in the throat–one of the leading
causes of side-effects in inhalation therapy (10). In order to
avoid such problems with MDIs, the use of spacer chamber is
recommended to reduce the velocity and droplet size of the
aerosol ultimately inhaled by the patient; thereby reducing the
oropharyngeal deposition (11).
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The magnitude of the fine particle (respirable) dose emitted
from DPIs has been clearly demonstrated to depend on the
airflow rate through many commercial devices (4, 6). Several
clinical studies report variability in the magnitude of inspiratory
flows generated by patients when using DPIs (6, 12, 13) and
many patients with lung disease struggle to inhale with sufficient
strength throughmedium-to-high resistance devices. The result
is high variability in the liberation of fine (inhalable) particles
from marketed DPIs that were well characterized using in vitro
testing (14, 15). Oropharyngeal deposition is high for DPIs (16,
17) due to the force of the inhalation manoeuvre being
insufficient to deaggregate drug/carrier mixtures effectively.
Low-to-medium resistance devices appear an effective option
for chronic obstructive pulmonary disease patients to achieve
the high inhalation flow rates required for effective
deagglomeration (18). Conversely, the inhalation of particles
at high velocities from DPIs promotes inertial impaction of
inhaled particles within the oropharynx (19).
There is clearly a challenge to address the oropharyngeal
deposition of DPIs, as well as minimize the variability between
patients in the aerodynamic diameter and respirable fractions
arising from flow rate variability. Studies from the late 1990s (20,
21) showed potential to reduce oropharyngeal deposition using
spacer devices for DPIs, similarly to with MDIs. A more recent
CFD-led study (computational fluid dynamics) developed a
spacer that improved aerosol penetration past the oropharynx
for Astra Zeneca’s Turbuhaler™ (22). In addition, spacer use at
low flow rates was also shown to reduce the fraction of large
particles reaching the oropharynx (23). The promise of such
early findings to translate into commercial or clinical success is
puzzling. However, it may be due to the specificity of the
prototypes for specific devices, and also because the properties
of the aerosol emitted from the DPI itself into the spacer remain
susceptible to the inter-patient variability in the flow rate.
In recent years, miniature cyclone technology has been
developed for DPIs to capture the particles with high
momentum liberating only the fine particles for inhalation
(e.g. the Airmax™) with improved consistency of delivered dose
at various flow rates (24). The Conix™ device family
incorporating reverse-flow cyclones, developed by Cambridge
Consultants Ltd. (25) and licensed by 3 M Drug Delivery
Systems (3 M Ltd) (26), effectively retain large agglomerates
inside the device. The technology employs a cyclone chamber
(cone section in Fig. 1) where an axially downward-flowing
vortex is formed upon inhalation. A secondary axially
upward-flowing vortex towards the exit orifice is formed at the
core due to the changing diameter of the conical region.
Particles of large mass and inertia are retained in the cone,
and only the finest particles (e.g. <5 μm) can escape the cyclone
for inhalation (26). Reverse-flow cyclones offer potential to
function as a DPI spacer to screen out the non-respirable
particles in aerosols emitted from conventional DPIs. However
for equivalency to the marketed product, passage through the
cyclone should not lead to further aerosol deagglomeration.
CFD investigations of miniature cyclones spacers (27, 28)
indicated the particle size output to be restricted to respirable
particles. As a result cyclone spacers with generic applicability to
lung drug delivery have been prototyped. The aim of the
current work was to investigate in vitro drug delivery for a range
of marketed inhalers with the prototypes to investigate
minimization of throat deposition from carrier-based DPIs.
MATERIALS AND METHODS
Materials
Micronized salbutamol sulphate (SS) was purchased from
GlaxoSmithKline Research and Development (Ware, UK).
Micronized fluticasone propionate (FP) was purchased from
Sicor de Mexico (Toluca, Mexico) and micronized budesonide
(Bud) was supplied from LGM Pharma (Boca Raton, USA).
Salmeterol xinafoate (SX) was purchased from Vamsi Labs Ltd
(Solapur, India). Lactose monohydrate, chromatography grade
methanol, hydrochloric acid solution (HCl) 5M, n-Hexane were
purchased from FisherScientific (Loughborough, UK).
Hipersolv® grade ammonium acetate was purchased from
Lab3 Ltd (Northampton, UK). A Luna 3 μm C18 column
(150 mm×4.6 mm×3 μm) was obtained from Phenomenex
(Macclesfield, UK). Silicone oil–Dow Corning Corporation
200® fluid was obtained from Sigma-Aldrich (Gillingham,
UK). The DPIs tested were an Easyhaler/Budesonide™
400 μg/dose (purchased from Orion Pharma, Newbury, UK),
a Seretide/Accuhaler™ 50 μg/500 μg/dose and Ventolin/
Accuhaler™ 200 μg/dose (purchased from Allen & Hanburys,
Uxbridge, Middlesex, UK) and a Cyclohaler® device (obtained
from AAH Hospital Supplies, Coventry, UK). Size 4 hard
gelatine capsules were obtained from Meadow Laboratories
Ltd. (Romford, UK). Cyclone spacers were manufactured in-
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Fig. 1 The reverse flow cyclone principle.
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house (University of Cambridge, UK) from Perspex blocks
(Engineering & Design Plastics Ltd, Cambridge, UK); the exit
duct was cut and polished from stock brass tubing (Engineering
Department Storeroom, University of Cambridge, UK). The
flow meter (model number DMF2), next generation impactor
(NGI) and a model HCP5 vacuum pump were all purchased
from Copley Scientific Ltd (Nottingham, UK).
Cyclone Manufacture
Two miniature reverse-flow cyclones (Cheng 1 and Cheng 2)
weremanufactured to have a theoretical particle cut-off diameter
below 5 μm for flow rates between 30 and 120 Lmin−1 (with
reference to empirical models of cyclone performance (29)). The
first cyclone (hereafter referred to as Cheng 1) was machined
from Perspex with a circular inlet orifice of diameter 4.1 mm to
facilitate relatively high inlet velocities with high pressure drops.
The second cyclone (hereafter: Cheng 2) with a 6×10 mm
rectangular slot inlet was then created with lower relative
pressure drops and inlet velocities. For dimensional accuracy,
easy sample collection and interchange ability both geometries
were manufactured in three separate sections: exit duct (top),
inlet and cylinder body (mid) and cone (bottom). The bottom of
the cone section had a through-hole for sample collection, which
was sealed during experiments. In Fig. 2 the dimensions of both
cyclones are reported. An inlet adapter was also manufactured
out of Perspex to enable connectivity with commercial DPI
devices (Fig. 3).
Quantitative Analysis by High Performance Liquid
Chromatography (HPLC)
TheHPLC instrument used was an Agilent 1050 Series (Agilent
Technologies UK Ltd., Edinburgh, UK). The stationary phase
was a Luna 3 μmC18 column (150 mm×4.6 mm×3 μm). The
mobile phase was filtered through a 0.2 μm nylon filter and
degassed by ultrasonication for 30 min. To analyze Bud the
mobile phase used was a 75:25 (v/v) mixture of methanol: 0.6%
(w/v) aqueous ammonium acetate. The column temperature
was set at 40°C with UV detection at 240 nm. To analyze SX
and FP the mobile phase used was the same as per Bud. The
column temperature was set at 40°C with UV detection at
228 nm. To analyze SS the mobile phase used was an 80:20
(v/v) mixture of 0.6% (w/v) aqueous ammonium acetate:
methanol and pH was adjusted to 4.5 with HCl 1 M. The
column temperature was set at 50°C with UV detection at
272 nm. For all the methods the flow rate was set at
1.00 ml min−1, with injection volume of 50 μl. To validate the
methods, the concentration range used was between 0.5 and
50 μg/ml for Bud, SX and FP, and 1–50 μg/ml for SS.
Cyclohaler® Capsule Filling
The mixture of micronized SS and lactose was removed from
marketed Ventolin/Accuhaler™ products. Size 4 hard gelatine
capsules (Meadow Laboratories Ltd., Romford, UK) were
accurately hand-filled with approximately 0.0125 g of the blend.
Aerosolization Assessment Using Next Generation
Impactor for Cheng 1
A solution of 1% of silicon oil in n-Hexane was prepared as
coating agent for the impactor plates of the NGI.
Approximately 15 ml of the solution was added into the first
stage, rotated and transferred into the second stage and so on
until the last stage was covered. The plates were left under the
fume hood in order to allow the hexane to evaporate leaving a
thin layer of silicon as coating.
Aerosolization studies were performed using the NGI with
a model HCP5 vacuum pump. The NGI was assembled
according to the requirements of the British Pharmacopeia.
The flow rates used were 30, 45, and 60 Lmin−1 (with each
actuation lasting 8.0, 5.3 and 4.0 s, respectively). The mixture
of micronized SS and lactose was removed from marketed
Ventolin/Accuhaler™ products. The Ventolin™ formulation
was aerosolized using a Cyclohaler® device with and without
the Cheng 1. 15 ml of mobile phase for SS was added in the
central cup of the pre-separator and the flow rate was adjusted
with the aid of a flow meter. Drug was recovered from the
device, capsules and NGI apparatus as follows. The
Cyclohaler® and the capsules were washed with 20 ml of
mobile phase and transferred into a volumetric flask. The
bottom of the cyclone, the mouthpiece and the throat were
each washed with 50 ml of mobile phase; whilst the upper
section of the cyclone was washed with 10 ml. For collecting
the drug from the pre-separator 100 ml of mobile phase was
used for washing and dissolution of deposited drug. The
volumetric flasks were sonicated using a sonicator (Kerry,
Germany) for 2 min. When the Cyclohaler® was employed
Cheng 1 Cheng 2
D 20 21
De 5.9 5.9
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H 57.9 56.4
h 24.7 23.5
S 17.3 23.5
B 6.2 7.1
Fig. 2 Dimensions of simulated cyclone geometries (units in mm). 1Cheng 1
was manufactured with a circular inlet orifice, diameter 4.1 mm.
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alone, 10 ml of mobile phase were added at the first 5 stages,
whilst 5 ml of solvent was used for the last 3 stages of the
impactor. All the stages were set on a laboratory rocker
(Stirling Mixer, Sandrest Ltd, UK) and rocked for 2 min in
order for the solvent to clean the entire surface. When the
Cyclohaler® was employed with the Cheng 1, 5 ml of mobile
phase was added to all the stages. The concentration of the
drug from each stage was determined by HPLC. After
performing the experiments, each stage and the NGI were
thoroughly cleaned with Millipore water and the coating was
removed with acetone and rinsed with methanol.
Aerosolization Assessment Using Next Generation
Impactor for Cheng 2
The second cyclone (Cheng 2) provided a lower resistance
to airflow (0.04 kPa1/2 min L−1) than Cheng 1 (0.06
kPa1/2 min L−1). Cyclohaler®, Seretide (500)/Accuhaler™
and Easyhaler (400)/budesonide™ were employed with and
without Cheng 2 at 2 and 4 kPa to represent values achievable
by patients. Each device with the Cheng 2 was connected to a
dose uniformity sampling apparatus (DUSA, Copley Scientific
Ltd., Nottingham, UK). The pressure drop was set accordingly
and the respective flow rate was measured with a flow meter.
2 kPa corresponded to 37 Lmin−1, 34 Lmin−1 and 31 Lmin−1
for the Cyclohaler®, Seretide/Accuhaler™ and Easyhaler/
budesonide™ in series with the Cheng 2, respectively, and
4 kPa to 51 Lmin−1, 50 Lmin−1, and 43 Lmin−1 for the
Cyclohaler®, Seretide/Accuhaler™ and Easyhaler/
budesonide™, in series with the Cheng 2, respectively. Each
DPI was also tested alone at the corresponding flow rates. Prior
to performing the measurements with the NGI, the desired flow
rate was adjusted with a flow meter. The NGI analysis and
sample recovery were performed as above for Cheng 1, with the
exception of the respectivemobile phase being employed in pre-
separator and for washing of the NGI stages.
Aerosolization Studies Using Laser Diffraction Analysis
Aerosolization of the active pharmaceutical ingredients (API)
from each device was performed by laser diffraction analysis
using the Sympatec Inhaler module (Inhaler Helos/KF,
Sympatec Limited, Bury, UK) with flow rates between 30
and 60 Lmin−1 from the Cyclohaler® device in absence and
presence of Cheng 1; and at 2 and 4 kPa for all the DPIs with
and without Cheng 2.
Data Analysis
The % recovery was calculated, for full mass balance, as the
total recovered drug (μg) on each stage and the device as a %
of the total known mass of the drug actuated (i.e. the dose
content). The recovered dose (RD) was calculated as the sum
of the dose (μg) in each stage of the NGI and device or the
NGI, device and spacer. The emitted dose (ED) was
calculated as the sum of the total dose recovered from the
NGI (or NGI and spacer) following actuation of the device.
The spacer-emitted dose (sED) was calculated as the sum of
the total dose recovered from the NGI only, following when
the spacer was used. The % retention of the cyclone was
calculated as the mass of drug deposited in the spacer as a
percentage of the ED. The % induction port/pre-separator
(IP/PS) deposition was calculated as the mass of drug
recovered on the IP/PS stage as a percentage of the ED or
the sED. The % fine particle fraction below 5 μm (FPF5μm)
was calculated following interpolation of the cumulative
Fig. 3 Photograph of reverse flow cyclone spacer prototype (Cheng 2).
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particle size distribution of the dose deposited on the NGI
stages as a percentage of the ED (i.e. ex device) or the sED (i.e.
ex cyclone). The mass median aerodynamic diameter values
(MMAD) were determined by interpolation of the cumulative
particle size distribution of the dose deposited on the impactor
stages.
Statistical Analysis
Statistical analysis was performed in Minitab using one-way
ANOVA and post-hoc Tukey’s test (multiple comparisons) or
Student’s two-tailed t -test for pair-wise comparisons, both at
95% confidence intervals.
RESULTS
Aerosolization Studies with Next Generation Impactor
Using Cheng 1
The emission of SS from Ventolin/Accuhaler™ formulation
using a Cyclohaler® DPI was assessed between 30 and
60 Lmin−1 with and without the Cheng 1 cyclone. The %
drug recovery was adequate at all the three flow rates with and
without the cyclone ranging from 79.44±2.90% to 81.45±
3.14% (Table I). The retention within the Cyclohaler® did
not change upon increasing the flow rate between 30 and
60 Lmin−1 (25.98±8.07% and 25.95±5.95% of RD
respectively, p value>0.05). When aerosolization was
performed with the add-on spacer, altering the flow rate did
not significantly alter the % deposited on the Cyclohaler®
(18.02±4.50% to 21.51±3.70% at 30 and 60 Lmin−1,
respectively p value>0.05, ANOVA). Deposition within
Cheng 1 was high, although it did decrease with increasing
flow rate (from 81.68±6.88% to 55.90±10.64%, at 30 and
60 Lmin−1, p value<0.05).
The results indicate that the presence of the cyclone
increased the respirable fraction of the total dose which would
be inhaled by patients (i.e. of the spacer-emitted dose, sED),
also called fine particle fraction below 5 μm (FPF5μm)
(Table I). When the cyclone was employed a dramatically
decreased induction port/pre-separator (IP/PS) deposition
was seen (p<0.05, Table I). The extent of IP/PS deposition
was unaffected by a change in the flow rate (p>0.05) due (in
part) to the variability between replicate analyses. Considering
the aerodynamic particle size distribution (PSD) of the aerosol
emitted into the impactor (Fig. 4), it was observed that the
majority of the dose from the DPI alone deposited in the
induction port/pre-separator (IP/PS)–the stages which collect
non-respirable particles. Conversely, when the cyclone was
employed themajority of the dose emitted from the spacer (i.e.
the dose which would be inhaled by a patient) penetrated
beyond the IP/PS to the sizeable stages. Figure 4 shows an
unconventional representation of the cumulative undersize
distribution. The calculation was based following the method
of Thiel (30) and Mitchell et al . (31, 32). Typically the aerosol
PSD is normalized for the impactor sizeable fraction only.
However, such a conventional representation does not
demonstrate the extent of the IP/PS deposition, which is
visible in Fig. 4 in the distributions calculated as % ED (blue
and black plots).
The fine particle fractions (FPF5μm % ED) of SS with dae<
5 μm are reported in Table I. The FPF5μm from the
Cyclohaler® increased from 20.83±3.00% to 33.84±
2.90% when the flow rates were increased (ANOVA,
p value<0.05). When the spacer was employed, considering
the FPF5μm (%ED), i.e. as a % of the total dose emitted from
the Cyclohaler® (Table I) there was no significant difference
between 45 and 60 Lmin−1. When the FPF5μm was expressed
as a % of the dose emitted from Cheng 1 (i.e. FPF %sED) it
was clear that the majority of the inhalable aerosol was
respirable, unlike when the Cyclohaler® was tested alone
Table I Aerosolisation of Salbutamol Sulphate from a Carrier Based Blend at 30, 45 and 60 Lmin−1 (Mean ± SD, n≥4) (IP/PS–Induction Port/Pre-Separator
Deposition, MMAD–Mass Median Aerodynamic Diameter, FPF5μm (ED)–Fine Particle Fraction <5 μm of the Emitted Dose)
Device Flow rate
(Lmin−1)
% drug
recovery
MMAD
(μm) IP/PS deposition % FPF5μm (ED)
Cyclohaler® 30 86.63±6.00 3.07±0.26 70.22±3.23 20.83±3.00
Cyclohaler® 45 83.06±3.59 2.49±0.22 66.34±3.38 27.86±3.50
Cyclohaler® 60 81.50±4.01 1.98±0.09 61.74±3.02 33.84±2.90
Expressed as % of
dose emitted DPI
(%ED)
Expressed as % of
dose emitted from
Cheng 1 (%sED)
Expressed as % of
dose emitted DPI
(%ED)
Expressed as % of
dose emitted from
Cheng 1 (%sED)
With Cheng 1 30 79.44±2.90 0.90±0.06 2.45±1.18 14.82±7.80 14.48±5.84 82.75±7.34
With Cheng 1 45 78.52±2.27 0.76±0.04 2.32±2.77 6.95±7.91 26.44±4.34 92.24±7.74
With Cheng 1 60 78.43±4.31 0.76±0.14 9.56±6.05 22.27±9.96 33.42±5.86 77.00±10.07
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(Table I, p<0.05). The FPF5μm (%sED) was not significantly
affected by flow rate (p>0.05). However, a high variability was
seen in the FPF5μm at the highest flow rate (77.00±10.07%).
The median aerodynamic diameter (MMAD) values (Table I)
were ~3 times smaller with Cheng 1 in place than for the
Cyclohaler® alone (ANOVA, post-hoc Tukey’s test, p<0.05).
The MMADs with the cyclone in place did not change upon
altering the flow rate (ANOVA, p>0.05). Thus the cyclone
served to reduce potential oropharyngeal deposition (i.e. IP/
PS deposition) whilst limiting particle output to the respirable
range, owing to the aerodynamic fractionation of the cyclone.
Particle Size Distribution for Cheng 1 Using Laser
Diffraction Analysis
In order to understand the lower FPF5μm and the variability in
IP/PS deposition with the cyclone at 60 Lmin−1, laser
diffraction analysis (LDA) on the emitted aerosol cloud was
performed using the Sympatec Inhaler module. LDA also
displayed the potential of the cyclone to retain large
agglomerates of micronized drug and carrier particles. The
volume median diameter (Dv50) of the aerosol cloud released
from the cyclone at 30 Lmin−1 was 1.03±0.01 μm which was
of the same order of magnitude as the MMAD and
substantially lower than when the cyclone was absent (40.04±
4.03 μm). The same trend was seen at 45 and 60 Lmin−1 when
the DV50 was 1.18±0.03 μm and 0.96 μm respectively. At the
higher flow rate, variability was observed in the particle size
distributions of the aerosol emitted from the cyclone (an
example of two size distribution measurements at 60 Lmin−1
are presented in Fig. 5). The bi-modal PSD indicated that some
agglomerates and/or carrier particles were observed to escape
the cyclone at the highest flow rate which would have resulted
in IP/PS deposition (only ~50% of the volume distribution was
<3 μm). However, the latter observations of agglomerate
emission displayed variability from actuation to actuation.
Aerosolization Studies Using Cheng 2–Compatibility
with Marketed Products
The Cheng 1 cyclone offered excessive resistance to inhalation
(0.06 kPa1/2 min L−1); therefore a second cyclone (Cheng 2) was
designed with a lower resistance (0.04 kPa1/2 min L−1). The
Aerosolization of SS from the Cyclohaler®, Bud from the
Easyhaler/Budesonide™ and SX/FP from the Seretide/
Accuhaler™ was assessed with and without Cheng 2. In order
to best simulate the way in which the combined spacer and DPI
would be used by a patient, testing was performed at the flow
rates necessary to achieve a pressure drop of either 2 or 4 kPa
across the two in series to study dose emission. 2 kPa
corresponded to a flow of 37 Lmin−1, 34 Lmin−1 and
31 Lmin−1 through the Cyclohaler®, Accuhaler™ and
Easyhaler™, respectively. 4 kPa corresponded to flows of
51 Lmin−1, 50 Lmin−1, and 43 Lmin−1 through the
Cyclohaler®, Accuhaler™ and Easyhaler™, respectively. The
percentage recoveries for all the APIs with and without the
Cheng 2 were within pharmacopoeial limits (Table II). The
Cheng 2 showed high retention of non-respirable drug as
observed for Cheng 1 (Table II) although no change was
detected when the flow rate increased (p>0.05).
The high retention in the spacer decreased the deposition of
the particles in the induction port/pre-separator stages (Table II)
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compared to when the devices were tested on their own. In the
case of Cyclohaler®/SS and Easyhaler/Budesonide™,
increasing the flow rate did not alter the IP/PS deposition (p>
0.05) both with and without the cyclone in place. The retention
of Bud within the Cheng 2 cyclone was lower than that of SS
(Table II, p<0.05). When the SX and FP were tested from the
Seretide/Accuhaler™, the IP/PS deposition was higher than
that of the SS and Bud at both flow rates (p<0.05, Table II).
IP/PS deposition of SX/FP remained higher than SS and Bud
when the cyclone was used. In addition to the reduction of the
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Fig. 5 Representative particle size distributions of salbutamol sulphate from the Cyclohaler® alone at 30 Lmin−1 (black circle ), 45 Lmin−1 (black up-pointing
triangle) and 60 Lmin−1 (black square ) and with the Cheng 1 at 30 Lmin−1 (white circle ), 45 Lmin−1 (white up-pointing triangle) and 60 Lmin−1 (white square ). The
data show the absence of the coarse lactose fraction when the spacer was used and the appearance of some agglomerates emitted from the Cheng 1 (x) at
60 Lmin−1 causing a bi-modal distribution.
Table II Values of % Drug Recovery, % Induction Port/Pre-Separator (IP/PS) Deposition and% RetentionWithin the Cheng 2 Cyclone for Salbutamol Sulphate
(SS), Budesonide (Bud), Salmeterol Xinafoate (SX) and Fluticasone Propionate (FP) Emitted from the Cyclohaler®, Easyhaler™ and Accuhaler™, Respectively at 2
and 4 kPa (Mean ± SD>4), ED is the Dose Emitted from the DPI and sED is the Dose Emitted from the Spacer
Drug Device % drug recovery Retention in the cyclone(% ED) IP/PS deposition
Pressure drop 2 kPa 4 kPa 2 kPa 4 kPa 2 kPa 4 kPa
SS Cyclohaler® 85.68±1.20 82.14±2.19 As % ED 67.28±2.09 64.44±2.49
Cyclone-Cyclohaler® 82.29±3.98 79.66±4.43 87.61±2.96 85.69±1.11 As % ED 2.22±1.51 2.66±0.59
As % sED 15.87±6.76 18.44±2.79
Bud Easyhaler™ 97.07±3.78 105.48±3.69 As % ED 62.01±2.52 63.18±3.72
Cyclone-Easyhaler™ 104.61±5.70 104.50±4.66 75.23±1.70 75.12±2.94 As % ED 3.89±0.61 3.73±0.59
As % sED 15.65±1.39 15.19±1.74
SX Accuhaler™ 88.94±9.10 97.73±2.96 As % ED 78.27±0.54 76.93±2.39
Cyclone-Accuhaler™ 89.56±10.58 101.25±13.56 80.48±0.56 83.05±3.67 As % ED 7.53±0.93 6.13±2.68
As % sED 38.70±4.56 36.01±9.77
FP Accuhaler™ 90.99±7.92 115.61±7.16 As % ED 78.21±1.87 75.53±3.50
Cyclone-Accuhaler™ 82.39±4.43 102.68±12.07 82.01±1.18 85.70±2.28 As % ED 6.38±0.46 4.15±1.19
As % sED 35.03±1.45 29.63±5.85
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IP/PS deposition with Cheng 2, the FPF5μm of the dose which
would be inhaled by the patient significantly improved (Fig. 6b,
compare FPF5μm %ED and FPF5μm %sED, (p<0.05)). All the
inhalers exhibited flow-rate dependence of the % FPF5μm when
employed alone (Fig. 6b). Easyhaler/Budesonide™ was the only
product where the change in flow rate altered the FPF5μm (p<
0.05) when the cyclone was employed.
The FPF5μm %sED differed significantly between the
products at both flow rates (SX Accuhaler™ < FP
Accuhaler™ < Bud Easyhaler™ = SS Cyclohaler®, p<0.05).
This was similar to the behaviour of the devices when tested
without the cyclone (i.e. comparing FPF5μm %ED). When the
cyclone was employed the fine particle dose (<5 μm, FPD) was
unaffected by a change in flow rate (p>0.05), with the exception
of the Easyhaler/Budesonide™ (p<0.05). However, with the
exception of SX, the FPDs of all inhaled drugs were significantly
lower (p<0.05) whenCheng 2 was employed (Fig. 6c). By way of
example, SS combined withCheng 2 (15.13±4.78 μg and 13.77
±1.67 μg at 2 and 4 kPa, respectively) was lower than from the
Cyclohaler® alone (31.64±2.70μg and 36.14±5.04μg at 2 and
4 kPa, respectively).
When the DPIs were tested alone, the MMADs decreased
markedly when the flow rate was increased (Fig. 6a, p<0.05).
The aerosols which would be inhaled by the patient (sED)
possessed lowerMMADs when emitted from the cyclone than
from the devices alone (Fig. 6a, p<0.05). For example, the
MMAD of SS was halved when the cyclone was employed
(Cyclohaler®: 3.00±0.12 μm and Cheng 2: 1.24±0.10 μm at
2 kPa). This showed the screening ability of Cheng 2, however
unlike Cheng 1, the MMADs were lower for all formulations
at the 4 kPa than 2 kPa flow rate with the cyclone in place
(Fig. 6a, p<0.05). The latter differences were not as large in
magnitude as when the DPIs were tested without the spacer.
Particle Size Distribution for Cheng 2 Using Laser
Diffraction Analysis
LDA was performed on the aerosol emitted from the
Cyclohaler®, Seretide/Accuhaler™ and Easyhaler/
Budesonide™ with and without Cheng 2 at 2 and 4 kPa. The
Dv50 was dramatically decreased when Cheng 2 was employed
for all the three different DPIs in the same manner of Cheng 1
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Fig. 6 (a ) Mass median aerodynamic diameter (MMAD), (b ) fine particle fraction <5 μm (FPF5μm), and (c ) fine particle dose <5 μm (FPD5μm); of salbutamol
sulphate (SS), budesonide (Bud), salmeterol xinafoate (SX) and fluticasone propionate (FP) emitted from the DPIs and from the DPIs through the Cheng 2
cyclone, (mean ± SX, n≥4).
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(Table III). With Seretide/Accuhaler™ escape of agglomerates
from the cyclone was observed, although the Dv50 values were
much reduced (1.73±0.16 and 1.15±0.12 μm, at 2 and 4 kPa,
respectively) compared to the Seretide/Accuhaler™ alone.
Similar to the variability in agglomerate emission from
actuation to actuation with Cheng 1 at high flow rates, a shift
in PSD to larger sizes was observed with Seretide/Accuhaler™
(indicated by the arrows in Fig. 7).
DISCUSSION
The aim of this study was to examine whether reverse-flow
cyclone devices are a suitable approach as a generic spacer to
overcome some of the practical and clinical difficulties of DPI
use. The latter difficulties include: excessive oropharyngeal
deposition (8) leading to side-effects such as dysphonia and
candidiasis (10); dependence of the respirable dose on the
inhalation flow rate (4, 33, 34); dependence of the
aerodynamic diameter on the inhalation flow rate (15). A
DPI containing a miniature reverse cyclone (Conix™) has
shown promise of increased FPF compared to a comparator
device at 4 kPa (26). We have attempted to extend the possible
benefits of improved FPFs by designing a generic platform
spacer which could be used by patients to reduce the
oropharyngeal deposition regardless of their prescribed DPI.
The two cyclone configurations designed fromCFD studies
(27, 28) that sought to minimize device resistance and achieve
an emission limited to the finest, respirable particles. The
investigations centred around three carrier-based
formulations: SS as Ventolin™ aerosolized using the
Cyclohaler® device; Bud aerosolized from the Easyhaler/
Budesonide™; and SX and FP aerosolized using the
Seretide/Accuhaler™. The latter list covers a variety of
particle physicochemical properties aerosolized from devices
covering the single-dose capsule, multiple single-dose and
reservoir multiple-dose platforms.
Both spacers were successful in terms of reducing potential
oropharyngeal deposition of the dose emitted from the device
as shown in Tables I and II. It was interesting that when the
cyclone was employed, the IP/PS deposition was not altered
regardless of flow rate, and was always below half that of the
DPI alone. Adequate mass balance was achieved throughout
all experiments (i.e. % recovered doses were within
pharmacopoeial limits), and the explanation for the reduced
IP/PS deposition was due to retention of the drug in the
cyclone spacer (e.g. 81.68±6.88% of SS at 30 Lmin−1 from
Cheng 1). Retention of drug within the spacer is a common
feature when spacers are employed with MDIs (35, 36) and is
beneficial in that oropharyngeal deposition is consequently
reduced. It was interesting to note that neither cyclone
retention nor IP/PS deposition was affected by the flow rate
for any of the drug-device formulations tested in the current
study. The IP/PS deposition was unaltered for SS whether
Cheng 1 or Cheng 2 was employed as the spacer. Although the
extent of IP/PS deposition and cyclone retention did depend
on the drug formulation/product type (Table II), the potential
for flow-rate independence of oropharyngeal drug deposition
for a specific formulation was a promising finding towards
overcoming inter-patient variability in DPI deposition profiles.
The mass median aerodynamic diameter (MMAD) is one
determinant (alongside inhalation parameters) of the potential
deposition site of an inhaled aerosol. It would be expected that
the MMADs for the aerosols emitted from the spacers would
be limited by the effective cut-off diameters of the cyclone itself
(27, 28) because the cyclone acts as a classifier, releasing only
particles smaller than the cut-off size. The MMAD values
(Table I) for SS with Cheng 1 in place were ~3 times smaller
than for the Cyclohaler® itself (ANOVA, post-hoc Tukey’s
test, p <0.05). Similar observations of reduction in the
MMAD were seen with Cheng 2 for all drugs studied, albeit
ranging between 2 and 3 fold reductions. Indeed theMMADs
were roughly equivalent to the calculated cut-off diameters of
the cyclones (Cheng 1~0.9 μm, Cheng 2~2 μm).
It appeared that the cyclone spacers did function effectively
as classifiers, a finding confirmed by laser diffraction analysis
(Figs. 5 and 7 and Table III). For both spacers, it was clear that
the non-respirable lactose fraction was retained in the spacer,
and the particle size output was limited (with some exceptions
discussed below) to particles with a geometric diameter below
the spacer cut-offs. Accepting that a change in MMAD
compared to the device alone is not desirable and challenges
equivalence of drug delivery, it is important to consider several
points. First, it appears that the MMAD was limited by the
effective cut-off diameter of the cyclone, and hence the
possibility for design optimization. Second, spacer use with
MDIs (although clinically accepted) is also associated with
altered MMADs and lung deposition fractions (37, 38).
Finally, it is accepted with DPIs that patients currently inhale
aerosols with a range of MMADs arising from their different
Table III Values of Volume Median Diameter (Dv50) of the Aerosol Clouds
Emitted from the Dry Powder Inhalers with and without Cheng 2 (Mean ±
SD, n=3)
API Device DV50 (μm)
Pressure drop 2 kPa 4 kPa
SS Cyclohaler® 58.66±3.42 61.56±3.18
Cyclone-Cyclohaler® 1.29±0.07 1.13±0.02
Bud Easyhaler™ 32.68±2.09 31.14±2.12
Cyclone-Easyhaler™ 1.88±0.02 1.68±0.05
SX/FP Accuhaler™ 48.13±2.03 46.01±2.99
Cyclone-Accuhaler™ 1.73±0.13 1.15±0.12
The data were obtained by laser diffraction analysis and identify the absence
the coarse carrier in the aerosol emitted from the cyclone
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inhalation performance (15, 18). It appears that particularly
with Cheng 1, the use of the cyclone minimized the changes in
the MMAD upon varying the flow rate observed with SS-
Cyclohaler® alone. This represents a possible advantage for
the use of a spacer with the DPI.
DPI spacers have been previously shown to reduce potential
oropharyngeal deposition (22, 23), however they have not
gained market acceptance. This may arise from the enhanced
deagglomeration shown by some workers (22, 23) and the
specificity of the spacers to a particular device (Turbuhaler
™) (20–23). The traditional view of spacer use with MDIs is
that extra-thoracic deposition is reduced but that the fine
particle deposition is unchanged when a spacer is employed
(39). The target with a DPI is therefore similar. It is necessary
to compare the FPF as a %ED (i.e. the dose exiting the device)
and examine its equivalency when the cyclone is used. The
FPF (%ED) of SS ranged from 20.83±3.00% (30 Lmin−1) to
33.84±2.90% (60 Lmin−1) from the Cyclohaler® (Table I).
With the exception of the lowest flow rate (30 Lmin−1), there
was no difference between the FPF (%ED) for the Cyclohaler®
and the Cyclohaler®-Cheng 1 combination. As well as
desiring consistency in the FPF (%ED) when the spacer is
employed, it is also important to consider the FPF (%sED),
because this indicates the dose which would be inhaled by the
patient. The benefit of the using the spacer is clear from Fig. 4
which indicates that the majority of the aerosol emitted from
Cheng 1 was respirable (ranging between 82.75±7.34% and
77.00±10.07% at 30 and 60 Lmin−1). The higher value of
FPF (%sED) compared to FPF (%ED) indicates the ability of
the spacer to remove the non-inhalable fraction of the aerosol
emitted from the Cyclohaler® at a particular flow rate. The
similarity of the values for 45 and 60 Lmin−1 were promising in
that the FPF appeared to be less affected by the alteration of
the flow rate with the cyclone in place (Table I) and this
represents an improvement over findings with previous DPI
spacers (21–23).
The promising findings with Cheng 1 were achieved using
a spacer with a cut-off diameter of ~0.9 μm, but a resistance to
airflow of (0.06 kPa1/2 min L−1) which is excessive. Following
CFD studies, the second Cheng 2 spacer was prototyped with
an inlet diameter which reduced resistance (0.04 kPa1/2
min L−1), with the compromise of a higher cut-off diameter
(~ 2 μm), albeit still in the respirable range. This level of
resistance was deemed to be appropriate because it is in the
centre of the range of other high resistance devices, e.g.
Turbuhaler™ (0.03 kPa1/2 min L−1) and Handihaler™
(0.05 kPa1/2 min L−1) (14, 40). The promising findings of the
reduced IP/PS (and hence potential oropharyngeal
deposition) were accompanied by a comparable FPF (%ED)
with and without the cyclone. Although the FPF of SS was
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Fig. 7 Representative particle size distribution of salmeterol xinafoate- and fluticasone propionate-containing aerosol clouds from Seretide/Accuhaler™ at 2 kPa
(black square ) and 4 kPa (black circle ) and from Cheng 2 at 2 kPa (white square) and 4 kPa (white circle). The data show the absence of the coarse lactose fraction
when the spacer was used and the emission of agglomerates from the cyclone (indicated by arrows ) for salmeterol xinafoate and fluticasone propionate blends at
2 kPa (white square ) and 4 kPa (white circle ).
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approximately halved by the use of the cyclone (p<0.05), with
the exception of SX and FP at the highest flow rate (4 kPa,
slightly lower, p<0.05), there were no significant differences in
the FPF (%ED) for Bud, SX or FP when the cyclone was
added to the DPI product (Fig. 6b). The latter findings were
also reflected in the fine particle dose (FPD) values (Fig. 6c). As
well as the comparability (excluding SS) to the DPI results, it
was important to note that using the cyclone minimized (or
removed) the magnitude of change in FPD and FPF (%ED),
caused by increasing the flow rates.
Differences in the FPF (% ED) when the cyclone is used
indicate pharmaceutical non-equivalence. However, it is also
important to consider the FPF (%sED)–i.e. the fraction of the
aerosol that would be inhaled by the patient when of assessing
the suitability of the cyclone device as a generic spacer. The
cyclone was designed to emit a similar FPF5μm (%sED) from
all products. There were clear differences in the FPF (% sED)
values observed in this study. The highest FPFs were seen for SS
and Bud (almost 80% of the dose emitted from the spacer). A
lower FPF5μm was observed for SX and FP from the Seretide/
Accuhaler™ (range 60–70%)whichwas due to the higher IP/PS
deposition of SX and FP compared to Bud and SS.Nevertheless,
the Cheng 2 cyclone delivered an aerosol which had a reduced
potential for oropharyngeal deposition (i.e. higher FPF %sED)
compared to all three DPI products tested (FPF %ED). Such a
reduction in IP/PS deposition is in accordance with
measurements for SS from the Conix™ DPI (26). The current
study has extended this showing the feasibility to combine a
generic spacer with several marketed DPI formulations or
devices to achieve similar potential clinical benefits.
It was notable that the FPF (%ED) for SS from Cheng 2
was markedly lower than from Cheng 1, attributable to the
higher retention of SS in Cheng 2 compared to Cheng 1
(Tables I and II). In addition, it was obvious that there were
differences in the level of IP/PS deposition, MMAD and
respirable fractions between the various formulation-device
combinations (Table II and Fig. 6). It must be borne in mind
that the factors governing deposition within induction ports
appear to be drug specific (41), however, it appeared from the
current study that the functioning of the reverse-flow cyclone
as a spacer depended crucially on the deagglomeration state of
the drug particles entering the cyclone. For example, laser
diffraction studies (Fig. 7) of the Seretide/Accuhaler™
formulation revealed the emission of some agglomerates that
escaped the cyclone. CFD studies highlighted the potential for
vortex instability within the conical region of the spacer which
would enable the escape of agglomerates (27, 28).
The role of the device in achieving deagglomeration of the
formulation prior to entry into the cyclone cannot be ignored
when considering the magnitude of the FPF (%sED) and the
IP/PS deposition. FPFs have been demonstrated to be reduced
with devices such as the Diskhaler™ due to the adherence of
deagglomerated powder to an impaction grid at the
mouthpiece (42). The similar rapid release of a powder plug
into the cyclone inlet from the Accuhaler™ device may not
have enabled deagglomeration to be as efficient for SX/FP as
for SS from the Cyclohaler®. In the Cyclohaler® a spinning
capsule aids powder dispersion and there is also an extended
mouthpiece where turbulent flow aids deagglomeration (43).
Meanwhile the Easyhaler™ has a design that maximizes
particle separation by changing the dimensions of the airflow
(44) prior to emission of the particles from the device.
The differences between the SS fine particle emission of
Cheng 1 and Cheng 2 spacers and the reduction of FPD for
FP but not SX when the flow rate through the Seretide/
Accuhaler™ was increased identify a further possible
explanation. There is potential that the cyclone does not solely
behave as a classifier, but that deagglomeration also takes
place within the cyclone vortices. Drug which adheres strongly
to the carrier is more difficult to aerosolize than drug which
forms agglomerates on the carrier surface (45). Bud (which
typically forms agglomerates with lactose) would be more
easily removed at equivalent flow rates from the carrier
surface than SS (which typically adheres to the surface),
thereby leading to higher Bud FPF values. Collisions between
particles and the cyclone wall or other particles in the cyclonic
flow aids powder dispersal (46), particularly collisions with
particles of large mass. Upon increasing the flow rate,
sufficient force is provided to break up drug agglomerates
further, but also aid removal of surface-adhered drug from
the carrier. Thus for example the FPF of SS fromCheng 1 was
significantly smaller at 30 Lmin−1 than at 45 or 60 Lmin−1. In
CFD studies (27, 28) of cyclone behaviour, it was observed
that greater turbulent dispersion forces exist in Cheng 1 owing
to its narrower cyclone inlet compared to Cheng 2. The
higher force for SS removal from the carrier under the
turbulent stress is one possible explanation for the higher
FPFs observed with the latter cyclone.
CONCLUSION
This study has demonstrated the potential to apply miniature
reverse-flow cyclones as a generic spacer platform for a range of
commercial carrier-based DPIs. The clear benefit in terms of
minimizing IP/PS (and hence) oropharyngeal deposition shows
the ability to improve the specificity of lung deposition for
patients whose inspiratory force is not strong enough to achieve
effective formulation deagglomeration and aerosolization. It
was also possible to control the aerodynamic particle size
distribution of the inhalable aerosol through the device
engineering that directs the cut-off diameter of the cyclone.
For example using the low cut-off diameters of the cyclones
studied herein, it may be possible to extend the ability of
marketed DPIs to achieve selective small airway deposition.
The study revealed the potential role of deagglomeration
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within the cyclone, and future work will be directed at
investigating the deagglomeration mechanisms within
miniaturized cyclones, particularly when tested with real
inhalation profiles which are achieved by patients through the
cyclones.
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